Login / Signup

In a multi-institutional cohort of myeloid sarcomas, NFE2 mutation prevalence is lower than previously reported.

Tauangtham AnekpuritanangMatthew M KlairmontJoel GradowskiKohei HagiwaraNathanael G BaileyPranil ChandraYiwei LiuHeather L MulderJohn EastonJinghui ZhangMichael G MartinAnna B OwczarczykJennifer B DunlapGuang FanRichard D PressPhilipp W Raess
Published in: Blood advances (2022)
Keyphrases
  • risk factors
  • dendritic cells
  • bone marrow
  • acute myeloid leukemia
  • high grade
  • immune response